Loading…
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Surge to Save Newborns Act
Client: ORCHARD THERAPEUTICS NORTH AMERICA · Firm: ORCHARD THERAPEUTICS NORTH AMERICA
FDA Policies: Rare Disease Gene Therapy Approvals Newborn Screening, including Appropriations and Accelerating Implementation and Providing Resources for States to Implement for Metachromatic Leukodystrophy (MLD) H.R. 10571: Surge to Save Newborns Act
MVP Act
Client: ORCHARD THERAPEUTICS NORTH AMERICA · Firm: ORCHARD THERAPEUTICS NORTH AMERICA
H.R. 7871: Medicaid Value-Based Payments for Patients (MVP) Act AKATCA and states' awareness of VBA's
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
ORCHARD THERAPEUTICS NORTH AMERICA via ORCHARD THERAPEUTICS NORTH AMERICA
2026 · third_quarter · Q3
FDA Policies: Rare Disease Gene Therapy Approvals Newborn Screening, including Appropriations and Accelerating Implementation and Providing Resources for States to Implement for Metachromatic Leukodystrophy (MLD) H.R. 10571: Surge to Save Newborns Act
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
Source: Senate LDA
MVP Act
Client: ORCHARD THERAPEUTICS NORTH AMERICA · Firm: ORCHARD THERAPEUTICS NORTH AMERICA
H.R. 7871: Medicaid Value-Based Payments for Patients (MVP) Act AKATCA and states' awareness of VBA's
2026 · first_quarter · 1A
Accelerating Kids' Access to Care Act and Pediatric Priority Review Voucher (Give Kids a Chance Act) FDA Policies: Rare Disease Gene Therapy Approvals Newborn Screening, including HRSA Appropriations & Fundings; RUSP Conditions
H.R. 7871: Medicaid Value-Based Payments for Patients (MVP) Act AKATCA and states' awareness of VBA's
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ORCHARD THERAPEUTICS NORTH AMERICA via ORCHARD THERAPEUTICS NORTH AMERICA
2026 · first_quarter · Q1
Accelerating Kids' Access to Care Act and Pediatric Priority Review Voucher (Give Kids a Chance Act) FDA Policies: Rare Disease Gene Therapy Approvals Newborn Screening, including HRSA Appropriations & Fundings; RUSP Conditions
H.R. 7871: Medicaid Value-Based Payments for Patients (MVP) Act AKATCA and states' awareness of VBA's
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE